DK165358C - Renset Bordetella pertussis antigen, vaccine indeholdende et sådant antigen og fremgangsmåde til isolering af et sådant ant - Google Patents

Renset Bordetella pertussis antigen, vaccine indeholdende et sådant antigen og fremgangsmåde til isolering af et sådant ant Download PDF

Info

Publication number: DK165358C
Authority: DK; Denmark
Prior art keywords: antigen; vaccine; pertussis; amino acid; supernatant
Prior art date: 1984-05-12

Application number

DK198502089A

Other languages

Danish (da)

English (en)

Other versions

DK208985D0 (da

DK165358B (da

DK208985A (da

Inventor

Pavel Novotny

Original Assignee

Evans Medical Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-05-12

Filing date

1985-05-10

Publication date

2000-11-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10560891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK165358(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1985-05-10 Application filed by Evans Medical Ltd filed Critical Evans Medical Ltd

1985-05-10 Publication of DK208985D0 publication Critical patent/DK208985D0/da

1985-11-13 Publication of DK208985A publication Critical patent/DK208985A/da

1992-11-16 Publication of DK165358B publication Critical patent/DK165358B/da

2000-11-06 Application granted granted Critical

2000-11-06 Publication of DK165358C publication Critical patent/DK165358C/da

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 41
241000588832 Bordetella pertussis Species 0.000 title claims abstract description 32
238000000034 method Methods 0.000 title claims abstract description 20
239000000427 antigen Substances 0.000 title claims description 44
108091007433 antigens Proteins 0.000 title claims description 44
102000036639 antigens Human genes 0.000 title claims description 44
239000000463 material Substances 0.000 claims abstract description 29
230000000694 effects Effects 0.000 claims abstract description 22
102000030621 adenylate cyclase Human genes 0.000 claims abstract description 16
108060000200 adenylate cyclase Proteins 0.000 claims abstract description 16
201000005702 Pertussis Diseases 0.000 claims abstract description 13
238000002360 preparation method Methods 0.000 claims abstract description 11
238000002955 isolation Methods 0.000 claims abstract 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 24
150000001413 amino acids Chemical class 0.000 claims description 16
239000006228 supernatant Substances 0.000 claims description 13
239000004471 Glycine Substances 0.000 claims description 12
238000004458 analytical method Methods 0.000 claims description 7
239000000243 solution Substances 0.000 claims description 7
239000004220 glutamic acid Substances 0.000 claims description 6
238000001155 isoelectric focusing Methods 0.000 claims description 6
230000036039 immunity Effects 0.000 claims description 5
239000002671 adjuvant Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
230000003834 intracellular effect Effects 0.000 claims description 3
238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims description 3
239000007853 buffer solution Substances 0.000 claims description 2
238000004255 ion exchange chromatography Methods 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
230000000890 antigenic effect Effects 0.000 abstract description 8
235000018102 proteins Nutrition 0.000 description 19
102000004169 proteins and genes Human genes 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 19
239000000499 gel Substances 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
239000000203 mixture Substances 0.000 description 14
238000012360 testing method Methods 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
235000001014 amino acid Nutrition 0.000 description 12
229940024606 amino acid Drugs 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000000872 buffer Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
238000009472 formulation Methods 0.000 description 8
229940066827 pertussis vaccine Drugs 0.000 description 8
239000011324 bead Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
239000011521 glass Substances 0.000 description 7
239000003547 immunosorbent Substances 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
229940030156 cell vaccine Drugs 0.000 description 6
239000002158 endotoxin Substances 0.000 description 6
238000002649 immunization Methods 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000000926 separation method Methods 0.000 description 6
241000282412 Homo Species 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
229920006008 lipopolysaccharide Polymers 0.000 description 5
238000000746 purification Methods 0.000 description 5
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
101710154643 Filamentous hemagglutinin Proteins 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
206010043376 Tetanus Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
206010013023 diphtheria Diseases 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
239000012149 elution buffer Substances 0.000 description 4
235000013922 glutamic acid Nutrition 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
238000003756 stirring Methods 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
239000000725 suspension Substances 0.000 description 4
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
101710116435 Outer membrane protein Proteins 0.000 description 3
108010081690 Pertussis Toxin Proteins 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
235000012538 ammonium bicarbonate Nutrition 0.000 description 3
239000001099 ammonium carbonate Substances 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
229960003983 diphtheria toxoid Drugs 0.000 description 3
238000000605 extraction Methods 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
229960004906 thiomersal Drugs 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
239000004474 valine Substances 0.000 description 3
FBEHFRAORPEGFH-UHFFFAOYSA-N Allyxycarb Chemical compound CNC(=O)OC1=CC(C)=C(N(CC=C)CC=C)C(C)=C1 FBEHFRAORPEGFH-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
101710110818 Dermonecrotic toxin Proteins 0.000 description 2
206010061217 Infestation Diseases 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
229910021538 borax Inorganic materials 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
229960005097 diphtheria vaccines Drugs 0.000 description 2
239000012634 fragment Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
238000009630 liquid culture Methods 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
235000010339 sodium tetraborate Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000001384 succinic acid Substances 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
229960002766 tetanus vaccines Drugs 0.000 description 2
238000011282 treatment Methods 0.000 description 2
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000005406 washing Methods 0.000 description 2
APUIQTDTBPKWKE-RNPGEKFLSA-N (2r,6s)-6-[[(4r)-4-[[(2s)-2-[2-[[(1r,2s,3r,4r,5r)-4-acetamido-2-[(2s,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,8-dioxabicyclo[3.2.1]octan-3-yl]oxy]propanoylamino]propanoyl]amino]-4-carboxybutanoyl]amino]-2-amino-7-[[(2r)-2-am Chemical compound O([C@@H]1[C@H]2CO[C@H](O2)[C@H](NC(C)=O)[C@H]1OC(C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@@H](N)C(O)=O)C(=O)NC(=O)[C@H](N)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O APUIQTDTBPKWKE-RNPGEKFLSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102100028218 Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241000588779 Bordetella bronchiseptica Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
108010038061 Chymotrypsinogen Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
101000724276 Homo sapiens Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 1 Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
101710194807 Protective antigen Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
229920002807 Thiomer Polymers 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
208000037386 Typhoid Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000011098 chromatofocusing Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000011365 complex material Substances 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
125000002791 glucosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
239000007973 glycine-HCl buffer Substances 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000003345 natural gas Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000005789 organism growth Effects 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229960000380 propiolactone Drugs 0.000 description 1
239000005297 pyrex Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000012925 reference material Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
201000008297 typhoid fever Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)

DK198502089A 1984-05-12 1985-05-10 Renset Bordetella pertussis antigen, vaccine indeholdende et sådant antigen og fremgangsmåde til isolering af et sådant ant DK165358C (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8412207		1984-05-12
GB848412207A GB8412207D0 (en)	1984-05-12	1984-05-12	Antigenic preparations

Publications (4)

Publication Number	Publication Date
DK208985D0 DK208985D0 (da)	1985-05-10
DK208985A DK208985A (da)	1985-11-13
DK165358B DK165358B (da)	1992-11-16
DK165358C true DK165358C (da)	2000-11-06

Family

ID=10560891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198502089A DK165358C (da)	1984-05-12	1985-05-10	Renset Bordetella pertussis antigen, vaccine indeholdende et sådant antigen og fremgangsmåde til isolering af et sådant ant

Country Status (13)

Country	Link
US (8)	US5648080A (fr)
EP (1)	EP0162639B1 (fr)
JP (3)	JPH07116053B2 (fr)
AT (1)	ATE61937T1 (fr)
CA (1)	CA1253073A (fr)
DE (1)	DE3582272D1 (fr)
DK (1)	DK165358C (fr)
ES (1)	ES8802275A1 (fr)
FI (1)	FI81262C (fr)
GB (1)	GB8412207D0 (fr)
LU (1)	LU90203I2 (fr)
NL (1)	NL980006I1 (fr)
NO (2)	NO165478C (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8412207D0 (en) *	1984-05-12	1984-06-20	Wellcome Found	Antigenic preparations
FR2597344B1 (fr) *	1986-04-16	1989-06-23	Merieux Inst	Perfectionnement au procede de purification d'antigenes proteiques de bacteries appartenant au genre bordetella, en vue de l'obtention d'un vaccin acellulaire.
US4762710A (en) *	1986-06-16	1988-08-09	The United States Of America As Represented By The Department Of Health And Human Services	Novel method of preparing toxoid by oxidation and metal ions
SE455946B (sv) *	1986-10-20	1988-08-22	Trion Forskning & Utveckling	Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner
FR2606789B1 (fr) *	1986-11-17	1991-05-31	Pasteur Institut	Preparations d'adenylate cyclase purifiees, procede d'obtention de ces preparations et leurs applications biologiques
EP0267998A1 (fr) *	1986-11-17	1988-05-25	Institut Pasteur	Moyens de protection contre l'infection et l'intoxication par bordetella
US5139776A (en) *	1987-04-24	1992-08-18	The Research Foundation For Microbial Diseases Of Osaka University	Method for culturing Bordetella pertussis, a pertussis toxoid and a pertussis vaccine
CA1337859C (fr) *	1987-04-24	1996-01-02	Masashi Chazono	Methode pour la culture de bordetella pertussis permettant d'obtenir l'anatoxine et un vaccin de la coqueluche
EP0338169B1 (fr) *	1988-04-19	1996-07-24	Institut Pasteur	Méthode d'obtention d'antigènes protecteurs contre les infections de Bordetella et contre les processus toxiques
EP0338170A1 (fr) *	1988-04-19	1989-10-25	Institut Pasteur	Protéine antigénique immunoprotectrice contre des bactéries pathogènes
GB8910570D0 (en)	1989-05-08	1989-06-21	Wellcome Found	Acellular vaccine
FR2646776B1 (fr)	1989-05-12	1994-06-03	Pasteur Institut	Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
EP0425082B1 (fr) *	1989-09-04	1995-04-26	Evans Medical Limited	Vaccins contre Bordetella
US5276142A (en) *	1989-12-11	1994-01-04	American Cyanamid Company	Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
US6197548B1 (en)	1990-04-02	2001-03-06	Medeva Pharma Limited	Transformed Pichia expressing the pertactin antigen
GB9007657D0 (en) *	1990-04-04	1990-05-30	Connaught Lab	Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) *	1990-07-11	1992-08-26	American Cyanamid Company	Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
GB9021004D0 (en) *	1990-09-27	1990-11-07	Wellcome Found	Acellular vaccines
US6444211B2 (en)	1991-04-03	2002-09-03	Connaught Laboratories, Inc.	Purification of a pertussis outer membrane protein
GB9304399D0 (en) *	1993-03-04	1993-04-21	Smithkline Beecham Biolog	Novel process
FR2728170A1 (fr) *	1994-12-15	1996-06-21	Pasteur Institut	Vaccin de type acellulaire anti-bordetella
FR2736064B1 (fr) *	1995-06-30	1997-09-05	Pasteur Institut	Epitopes protecteurs de l'adenyl cyclase-hemolysine(ac-hty). leur application au traitement ou a la prevention des infections par bordetella
ZA981370B (en) *	1997-02-20	1998-09-07	Cerberus Developments Bv	Method and apparatus for continuous flow isoelectric focusing for purifying biological substances
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
AU2014224556B2 (en)	2013-03-08	2016-10-06	Janssen Vaccines & Prevention B.V.	Acellular pertussis vaccine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3141824A (en) *	1961-05-19	1964-07-21	Lilly Co Eli	Pertussis antigen
US3395219A (en) *	1964-12-11	1968-07-30	Merck & Co Inc	Process for production of pertussis antigen
US3465078A (en) *	1965-10-21	1969-09-02	Sydney Z Spiesel	Method of recovering antigens from bordetella pertussis cells
FR2047886A1 (en) *	1969-06-30	1971-03-19	Merieux Inst	Non-toxic anti-whooping cough vaccine
FR2393065A1 (fr) *	1977-05-31	1978-12-29	Merieux Inst	Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis
EP0004137B1 (fr) *	1978-02-17	1981-11-11	National Research Development Corporation	Préparations immunologiques d'enveloppes cellulaires
GB2014452B (en) *	1978-02-17	1982-07-21	Secr Social Service Brit	Producing cell envelope preparations
JPS5750925A (en) *	1980-09-12	1982-03-25	Takeda Chem Ind Ltd	Preparation of pertussis toxoid
US4551429A (en) *	1983-09-15	1985-11-05	American Home Products Corporation	Stimulation of antigen production by Bordetella pertussis
US5237052A (en) *	1984-05-12	1993-08-17	Burroughs Wellcome Company	Antigenic preparations and isolation of such preparations
GB8412207D0 (en) *	1984-05-12	1984-06-20	Wellcome Found	Antigenic preparations
US4705686A (en) *	1986-05-09	1987-11-10	American Cyanamid	Process for the preparation of acellular Bordetalla pertussis vaccine
FR2606789B1 (fr) *	1986-11-17	1991-05-31	Pasteur Institut	Preparations d'adenylate cyclase purifiees, procede d'obtention de ces preparations et leurs applications biologiques
EP0267998A1 (fr) *	1986-11-17	1988-05-25	Institut Pasteur	Moyens de protection contre l'infection et l'intoxication par bordetella
GB8807860D0 (en) *	1988-04-05	1988-05-05	Connaught Lab	Pertussis vaccine
US5101014A (en) *	1989-02-10	1992-03-31	United States Of America	Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
GB8910570D0 (en) *	1989-05-08	1989-06-21	Wellcome Found	Acellular vaccine
US5276142A (en) *	1989-12-11	1994-01-04	American Cyanamid Company	Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007416D0 (en) *	1990-04-02	1990-05-30	Wellcome Found	Expression of heterologous protein in yeast
GB9007657D0 (en) *	1990-04-04	1990-05-30	Connaught Lab	Purification of a pertussis outer membrane protein(omp69)
IT1248735B (it) *	1990-06-21	1995-01-26	Sclavo Spa	Vaccini acellulari contro la pertosse
EP0484621A3 (en)	1990-07-11	1992-08-26	American Cyanamid Company	Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens

1984
- 1984-05-12 GB GB848412207A patent/GB8412207D0/en active Pending
1985
- 1985-05-10 DK DK198502089A patent/DK165358C/da not_active IP Right Cessation
- 1985-05-10 EP EP85303302A patent/EP0162639B1/fr not_active Expired - Lifetime
- 1985-05-10 FI FI851859A patent/FI81262C/fi not_active IP Right Cessation
- 1985-05-10 AT AT85303302T patent/ATE61937T1/de active
- 1985-05-10 ES ES543026A patent/ES8802275A1/es not_active Expired
- 1985-05-10 CA CA000481336A patent/CA1253073A/fr not_active Expired
- 1985-05-10 JP JP60099413A patent/JPH07116053B2/ja not_active Expired - Lifetime
- 1985-05-10 DE DE8585303302T patent/DE3582272D1/de not_active Revoked
- 1985-05-10 NO NO851878A patent/NO165478C/no not_active IP Right Cessation
1994
- 1994-03-21 US US08/210,458 patent/US5648080A/en not_active Expired - Lifetime
- 1994-05-11 US US08/240,814 patent/US5438120A/en not_active Expired - Lifetime
1995
- 1995-06-07 US US08/478,046 patent/US6048700A/en not_active Expired - Lifetime
- 1995-06-07 US US08/470,590 patent/US6127151A/en not_active Expired - Lifetime
1997
- 1997-08-01 NO NO1997010C patent/NO1997010I1/no unknown
1998
- 1998-01-27 NL NL980006C patent/NL980006I1/nl unknown
- 1998-01-28 LU LU90203C patent/LU90203I2/fr unknown
1999
- 1999-06-17 US US09/334,690 patent/US6210685B1/en not_active Expired - Fee Related
- 1999-06-30 US US09/343,399 patent/US20020150595A1/en not_active Abandoned
- 1999-07-07 JP JP11193312A patent/JP2000053585A/ja active Pending
- 1999-07-07 JP JP11193416A patent/JP2000072690A/ja active Pending
2002
- 2002-09-16 US US10/243,930 patent/US20030077294A1/en not_active Abandoned
- 2002-12-27 US US10/329,946 patent/US20030108572A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO165478C (no)	1991-02-20
US6127151A (en)	2000-10-03
LU90203I2 (fr)	1998-04-06
NO851878L (no)	1985-11-13
NL980006I1 (nl)	1998-04-01
US5438120A (en)	1995-08-01
ATE61937T1 (de)	1991-04-15
ES543026A0 (es)	1988-05-01
GB8412207D0 (en)	1984-06-20
DK208985D0 (da)	1985-05-10
DK165358B (da)	1992-11-16
US6210685B1 (en)	2001-04-03
JP2000072690A (ja)	2000-03-07
ES8802275A1 (es)	1988-05-01
JP2000053585A (ja)	2000-02-22
US20030077294A1 (en)	2003-04-24
US6048700A (en)	2000-04-11
FI81262B (fi)	1990-06-29
JPH07116053B2 (ja)	1995-12-13
FI851859L (fi)	1985-11-13
FI851859A0 (fi)	1985-05-10
US20030108572A1 (en)	2003-06-12
NO165478B (no)	1990-11-12
EP0162639A2 (fr)	1985-11-27
DE3582272D1 (de)	1991-05-02
US20020150595A1 (en)	2002-10-17
JPS60246321A (ja)	1985-12-06
NO1997010I1 (no)	1997-08-25
FI81262C (fi)	1990-10-10
US5648080A (en)	1997-07-15
EP0162639A3 (en)	1988-02-03
DK208985A (da)	1985-11-13
CA1253073A (fr)	1989-04-25
EP0162639B1 (fr)	1991-03-27

Legal Events

Date	Code	Title	Description
2000-05-15	PPF	Opposition filed
2005-05-30	PUP	Patent expired

Publication	Publication Date	Title
DK165358C (da)	2000-11-06	Renset Bordetella pertussis antigen, vaccine indeholdende et sådant antigen og fremgangsmåde til isolering af et sådant ant
AU714493B2 (en)	2000-01-06	Multivalent DTP-polio vaccines
EP0432203A1 (fr)	1991-06-19	Vaccins contre la legionellose et procedes pour leur production
JPS6051120A (ja)	1985-03-22	単純ヘルペスサブユニットワクチン
AU641711B2 (en)	1993-09-30	Process for purification of a 69 000 dalton antigenetic protein from bordetella pertussis
Novotny et al.	1991	Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine
KR101617464B1 (ko)	2016-05-02	Ｉｐｖ―ｄｐｔ 백신
PT90310B (pt)	1994-09-30	Processo para a obtencao de preparacoes de adenilato-ciclase
CN102584958A (zh)	2012-07-18	百日咳杆菌69kd外膜蛋白的纯化方法
DK172329B1 (da)	1998-03-23	Polydisperse, native Pseudomonas-flagella(H)-antigener (FAg) i polymer form og fremgangsmåde til deres udvinding
US5237052A (en)	1993-08-17	Antigenic preparations and isolation of such preparations
GB2062463A (en)	1981-05-28	Babesiosis vaccine
EP0002645B1 (fr)	1982-01-06	Complexe antigénique de neisseria gonorrhoeae, procédé et vaccin
JPH0272200A (ja)	1990-03-12	百日咳トキソイドワクチン
JPS59110626A (ja)	1984-06-26	Ｂ−オリゴマ−含有百日咳ワクチンおよびその製造方法
Peterson	1982	Pathogenesis of Salmonellosis: Salmonella Exotoxins
BRPI0202458B1 (pt)	2018-02-27	Processo de obtenção de vacina pertussis acelular
HK1016191A1 (zh)	1999-10-29	無細胞百日咳疫苗和其製備方法
HK1016191B (en)	2009-04-24	Acellular pertussis vaccines and methods of preparation thereof